We describe two suspected cases of pseudohypoparathyroidism type 1a or 1c with negative genetic test for mutations in the GNAS gene but with a common polymorphism in heterozygosis. No GNAS gene mutations are detected in 30-40% of pseudohypoparathyroidism so many of their molecular mechanisms are not known. We think that polymorphism c.393C>T(p.Ile131Ile) could be a new mutation related to pseudohypoparathyroidism.
INTRODUCTION
A new mutation associated with pseudohypoparathyroidism? 2 case reports.
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CASE REPORTS
We describe the clinical case of 2 childbearing age women with thyroid dysfunction, hypocalcemia, hyperphosphatemia, and high levels of PTH. In both cases, mineral metabolism was normal in first-degree relatives. Both patients are asymptomatic and remain safe levels of calcium under treatment with calcium and vitamin D.
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Pseudohypoparathyroidism is a metabolic disorder characterized by peripheral resistance to the action of parathyroid hormone (PTH) which can associate other hormonal disturbances. Their molecular basis is a defect in adenylate cyclase Gs system encoded by the GNAS gene receptor.
Clinical and analytical variables Different phenotypic and biochemical expressions of pseudohypoparathyroidism
Note: Reference values: calcium 8.5-10.10 mg/dl, phosphorus 2.70-4.5 mg/dl, PTH 7-74 pg/ml and vitamin D > 30 ng/ml.
Treatment with vitamin D or analogues is necessary to normalize serum calcium. Fixed preparations of calcium and vitamin D are not recommended. Treatment must get low-normal range of serum calcium. Use thiazides if there is significant hypercalciuria. In this cases, an ophthalmologic examination and renal ultrasound should be done to exclude cataracts and nephrolithiasis/nephrocalcinosis, respectively. Teriparatide or synthetic PTH 1-34 could be an option in patients with evidence or risk of nephrocalcinosis, because it normalizes serum calcium without increasing calciuria.
Treatment

